Axinn Successfully Represents Alvogen Before FTC
November 3, 2015
Axinn successfully represented Alvogen before the Federal Trade Commission in connection with Alvogen’s approval to buy the divestiture products in the proposed Mylan/Perrigo transaction. Mylan’s bid for Perrigo is valued at $25 billion, and Alvogen will acquire seven separate pharmaceutical products as a result of the FTC-mandated and approved divestiture. Alvogen was also approved to acquire the divestiture products in Pfizer/Hospira earlier this year. The FTC’s Mylan press release can be found here.
The Axinn team based in Washington, DC consisted of partner Michael Keeley, assisted by associate Kenina Lee.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Healthcare Antitrust Year-In-Review Webinar
Webinar
Antitrust
Axinn Antitrust Insight: FTC Announces Revised HSR Thresholds for 2026
Axinn Viewpoints
Antitrust
Axinn Announces Nominations for the Concurrences 2026 Antitrust Writing Awards
Awards & Recognitions
Antitrust
SABA North America Corporate Counsel Retreat 2026
Speaking Engagement
Antitrust
Axinn Promotes Lindsey Strang Aberg, Rebecca L. Clegg, Allison Vissichelli, and Eva Yung to Partner; Ricardo Camposanto, Danielle D. Irvine, and Josh Jowdy to Counsel
News
Antitrust

